Here is the clinical profile of Buprenorphine (0.4 mg) + Naloxone (0.1 mg) Sublingual Tablet โ without brand names:
๐ Buprenorphine 0.4 mg + Naloxone 0.1 mg (Sublingual Tablet)
โ DESCRIPTION
This is a combination sublingual tablet used primarily in the treatment of opioid dependence.
- Buprenorphine is a partial opioid agonist, reducing cravings and withdrawal.
- Naloxone is an opioid antagonist, included to prevent misuse by injection.
When taken sublingually as directed, naloxone has minimal effect. If injected, it blocks opioid effects and may precipitate withdrawal โ discouraging abuse.
๐งช FORMULATION
- Active Ingredients:
- Buprenorphine hydrochloride โ 0.4 mg
- Naloxone hydrochloride โ 0.1 mg
- Form: Sublingual tablet
- Route: Sublingual (under the tongue)
๐ฟ NATURE
- Buprenorphine: Partial ยต-opioid receptor agonist & ฮบ-receptor antagonist
- Naloxone: Pure opioid antagonist (competitive blocker at ยต-receptors)
๐ USES
- Maintenance therapy for opioid dependence
- Detoxification phase for opioid use disorder
- Helps reduce illicit opioid use by stabilizing the patient
๐ ADVANTAGES
- Lower abuse potential than buprenorphine alone
- Reduces withdrawal symptoms and cravings
- Naloxone deters IV abuse
- Can be administered in outpatient settings under supervision
- Lower risk of respiratory depression than full opioid agonists
โ ๏ธ PRECAUTIONS
Common Side Effects:
- Headache, insomnia, dizziness
- Sweating, constipation, nausea
- Anxiety, depression, dry mouth
Serious Risks:
- Respiratory depression (especially with sedatives/alcohol)
- Hepatic impairment
- Precipitated withdrawal if started too early
- Risk of misuse if not monitored
โ CONTRAINDICATIONS
- Known hypersensitivity to either component
- Severe respiratory depression
- Acute alcohol, benzodiazepine, or barbiturate intoxication
๐ฉโโ๏ธ USE IN SPECIAL POPULATIONS
- Pregnancy: Use only if benefits outweigh risks โ may cause neonatal opioid withdrawal
- Breastfeeding: Monitor infant; low levels in breast milk
- Children: Not approved below 16 years
- Elderly: Use with caution due to altered metabolism
๐ INTERACTIONS
- CNS depressants (alcohol, benzodiazepines, antipsychotics) โ โ risk of respiratory depression
- CYP3A4 inhibitors (e.g. erythromycin) โ โ buprenorphine levels
- CYP3A4 inducers โ โ effectiveness
- May interact with antidepressants and antihypertensives
๐ก ADMINISTRATION ADVICE
- Place under the tongue and let dissolve fully
- Do not chew, swallow, or inject
- Avoid eating or drinking until dissolved
- Initial dosing should be supervised
- Use with caution in opioid-naive patients
๐ง STORAGE
- Store at 20โ25ยฐC (68โ77ยฐF)
- Protect from light and moisture
- Controlled substance โ secure storage mandatory
- Keep away from children